Oncotelic Therapeutics (OTCQB: OTLC) has introduced PDAOAI, an evidence-interrogation platform that indexes more than 125,000 PubMed abstracts on TGF-β signaling. Unlike traditional predictive models that rely on black-box predictions, PDAOAI enables researchers to interrogate the evidence directly, generating testable and auditable hypotheses. This approach is designed to reduce training-set bias and build transparent, reproducible chains from question to evidence to hypothesis, a core challenge in biotech research.
The pharmaceutical industry is undergoing a structural transition, with regulatory agencies raising expectations around data integrity and traceability. The shift from retrospective audits toward continuous, AI-enabled monitoring systems is reshaping drug discovery. Oncotelic's PDAOAI platform responds to this environment by organizing and connecting large volumes of biomedical literature, allowing researchers to identify patterns and generate hypotheses with direct links to source evidence. Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations.
The hypothesis-first methodology addresses the growing challenge of manual processes and isolated datasets in an era of rapidly expanding scientific literature. By leveraging PDAOAI, researchers can navigate the global TGF-β literature more effectively, supporting continuous, defensible documentation that meets modern regulatory standards. The platform's retrieval-and-interrogation approach ensures that hypotheses are grounded in published evidence, enhancing transparency and reproducibility in drug discovery.
For more information about Oncotelic and its PDAOAI platform, visit the company's newsroom at ibn.fm/OTLC. BioMedWire, a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, provided coverage of this announcement. BioMedWire is part of the Dynamic Brand Portfolio @IBN, which offers access to a vast network of wire solutions, article syndication to 5,000+ outlets, enhanced press release services, and social media distribution. For more information, visit https://www.BioMedWire.com.
This development underscores the industry's move toward AI-driven, evidence-based research methodologies, positioning PDAOAI as a tool that could accelerate discoveries in TGF-β signaling and related therapeutic areas. As the pharmaceutical sector continues to integrate AI into its operations, platforms like PDAOAI may play a crucial role in bridging the gap between vast biomedical data and actionable research insights.
